Annual Reports

 
Quarterly Reports

 
8-K

  • 8-K (Mar 12, 2009)
  • 8-K (Mar 4, 2009)
  • 8-K (Feb 24, 2009)
  • 8-K (Feb 12, 2009)
  • 8-K (Jan 23, 2009)
  • 8-K (Dec 10, 2008)

 
Other

Panacos Pharmaceuticals 8-K 2005

Documents found in this filing:

  1. 8-K
  2. Ex-99.1
  3. Ex-99.1
FORM 8-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 8-K

 


 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 30, 2005

 

V. I. TECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   0-24241   11-3238476

(State or other jurisdiction

of incorporation)

  (Commission File Number)  

(IRS Employer

Identification No.)

 

134 Coolidge Avenue

Watertown, Massachusetts 02472

(Address of principal executive offices and zip code)

 

Registrant’s telephone number, including area code: (617) 926-1551

 


 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 



ITEM 8.01 OTHER EVENTS

 

On June 30, 2005, V.I. Technologies, Inc. (“Vitex” or the “Company”) provided a corporate update, including the status of key clinical and development programs and announced its plans to discontinue direct investment in the development of the INACTINE system for red blood cells while undertaking efforts to license the technology and intellectual property to potential partners. It also announced its intention to seek shareholder approval to change the corporate name to Panacos Pharmaceuticals. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference. The information in this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

 

(c) Exhibits:

 

Exhibit

No.


  

Description


99.1    Press Release of V.I. Technologies, Inc. dated June 30, 2005


SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

V. I. TECHNOLOGIES, INC.

 

Dated: June 30, 2005

 

By:    /s/ John R. Barr            

John R. Barr

President and Acting Chief Financial Officer


EXHIBIT INDEX

 

Exhibit

No.


  

Description


99.1    Press Release of V.I. Technologies, Inc. dated June 30, 2005
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki